where we inject human pathological tau into P301S transgenic mice. And so we want to be sure we exceed those, what the EC50, if you will, of that effect of impeding spread. And we're pretty ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

The company has advanced its VY1706 tau silencing gene therapy to IND-enabling studies and completed a single ascending dose study for its VY7523 anti-tau antibody. Despite these advancements ...

Institute of Biological Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Road, Nankang, Taipei 115, Taiwan Institute of Biochemical Sciences, National Taiwan ...

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...

Voyager Therapeutics continues to focus on neurotherapeutics, with a particular emphasis on central nervous system (CNS) diseases such as Alzheimer’s. The company has advanced its VY1706 tau silencing ...